# A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT06126237** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CM313 injection

## Key facts

- **NCT ID:** NCT06126237
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-28
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126237, "A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06126237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*